scholarly journals Limbic Encephalitis Associated with Anti-Voltage-Gated Potassium Channel Complex Antibodies as a Cause of Adult-Onset Mesial Temporal Lobe Epilepsy

2014 ◽  
Vol 36 (2) ◽  
pp. 129-133 ◽  
Author(s):  
Tomoko TOYOTA ◽  
Naoki AKAMATSU ◽  
Sadatoshi TSUJI ◽  
Shigeru NISHIZAWA
Keyword(s):  
Temporal Lobe Epilepsy ◽  
Potassium Channel ◽  
Temporal Lobe ◽  
Limbic Encephalitis ◽  
Mesial Temporal Lobe Epilepsy ◽  
Adult Onset ◽  
Voltage Gated ◽  
Mesial Temporal Lobe

scholarly journals Linkage study of voltage-gated potassium channels in familial mesial temporal lobe epilepsy

2007 ◽  
Vol 65 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Cláudia Vianna Maurer-Morelli ◽  
Rafael Breglio Marchesini ◽  
Rodrigo Secolin ◽  
Neide Ferreira Santos ◽  
Eliane Kobayashi ◽  
...  
Keyword(s):  
Potassium Channels ◽  
Temporal Lobe Epilepsy ◽  
Temporal Lobe ◽  
Critical Role ◽  
Mesial Temporal Lobe Epilepsy ◽  
Linkage Study ◽  
Linkage Data ◽  
Mesial Temporal Sclerosis ◽  
Voltage Gated ◽  
Mesial Temporal Lobe

Voltage-gated potassium channels (VGKCs) play a critical role in the regulation of neuronal excitability and have been implicated in some types of epilepsies. Recently, autoimmune limbic encephalitis (LE) was associated with antibodies against VGKC. In addition, patients with LE showed partial epilepsy and increased T2 signal abnormalities in limbic structures. We have reported familial mesial temporal lobe epilepsy (FMTLE) associated with hippocampal atrophy (HA) and other signs of mesial temporal sclerosis detected by magnetic resonance imaging (MRI). In order to investigate whether VGKC may be associated to HA present in FMTLE, we perform linkage study in these candidate genes. Seventy-three microsatellites markers were genotyped in different human autosomal chromosome. Two-point LOD scores did not show evidence for linkage with any of the microsatellite markers genotyped (Zmax ranging from 0.11to-9.53 at theta=0.00). In the present study, linkage data showed no evidence that VGKC are involved in the determination of HA in FMTLE.

scholarly journals Stereotactic EEG-guided radiofrequency thermocoagulation versus anterior temporal lobectomy for mesial temporal lobe epilepsy with hippocampal sclerosis: study protocol for a randomised controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Yi-He Wang ◽  
Si-Chang Chen ◽  
Peng-Hu Wei ◽  
Kun Yang ◽  
Xiao-Tong Fan ◽  
...  
Keyword(s):  
Temporal Lobe Epilepsy ◽  
Temporal Lobe ◽  
Hippocampal Sclerosis ◽  
Controlled Trial ◽  
Mesial Temporal Lobe Epilepsy ◽  
Temporal Lobectomy ◽  
Anterior Temporal Lobectomy ◽  
Radiofrequency Thermocoagulation ◽  
Mesial Temporal Lobe ◽  
Randomised Controlled

Abstract Introduction In this report, we aim to describe the design for the randomised controlled trial of Stereotactic electroencephalogram (EEG)-guided Radiofrequency Thermocoagulation versus Anterior Temporal Lobectomy for Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (STARTS). Mesial temporal lobe epilepsy (mTLE) is a classical subtype of temporal lobe epilepsy that often requires surgical intervention. Although anterior temporal lobectomy (ATL) remains the most popular treatment for mTLE, accumulating evidence has indicated that ATL can cause tetartanopia and memory impairments. Stereotactic EEG (SEEG)-guided radiofrequency thermocoagulation (RF-TC) is a non-invasive alternative associated with lower seizure freedom but greater preservation of neurological function. In the present study, we aim to compare the safety and efficacy of SEEG-guided RF-TC and classical ATL in the treatment of mTLE. Methods and analysis STARTS is a single-centre, two-arm, randomised controlled, parallel-group clinical trial. The study includes patients with typical mTLE over the age of 14 who have drug-resistant seizures for at least 2 years and have been determined via detailed evaluation to be surgical candidates prior to randomisation. The primary outcome measure is the cognitive function at the 1-year follow-up after treatment. Seizure outcomes, visual field abnormalities after surgery, quality of life, ancillary outcomes, and adverse events will also be evaluated at 1-year follow-up as secondary outcomes. Discussion SEEG-guided RF-TC for mTLE remains a controversial seizure outcome but has the advantage for cognitive and visual field protection. This is the first RCT studying cognitive outcomes and treatment results between SEEG-guided RF-TC and standard ATL for mTLE with hippocampal sclerosis. This study may provide higher levels of clinical evidence for the treatment of mTLE. Trial registration ClinicalTrials.gov NCT03941613. Registered on May 8, 2019. The STARTS protocol has been registered on the US National Institutes of Health. The status of the STARTS was recruiting and the estimated study completion date was December 31, 2021.

Sign in / Sign up

Export Citation Format

Share Document